NCI Community Oncology Research Program Accrual Analysis August 2014-July 2018

Clinical Trials and Translational Research Advisory Committee November 7, 2018

> Worta McCaskill-Stevens, M.D., M.S. Chief, Community Oncology and Prevention Trials Research Group Division of Cancer Prevention



A program of the National Cancer Institute of the National Institutes of Health


NCORP Accrual Analysis

- NCORP Structure to Support Accrual
- Accrual by Research Type
- Characteristics of NCORP Patients/Participants
- Concept/Protocol Timelines

NCORP Research Portfolio


- Cancer Control, Prevention, Screening, Post-Treatment Surveillance
- Quality of Life Embedded in Treatment Trials
- Cancer Care Delivery
- Advanced Imaging and Treatment Trials

Sources of NCORP Trials/Studies: Research Bases




National Clinical Trials Network (NCTN) Group & NCORP Research Base

Sources of NCORP Academic/ Community Partnership




NCORP Community Site, M/U Community Site and Research Bases Geographic and Organizational Diversity




Average Number of Trials Available per Year

2014	46
2015	43
2016	44
2017	46
2018	48

NCORP Cancer Control/Prevention Accrual by Year: CP/C 8/1/14 – 7/31/18 TREATMENT





NCORP Cancer Control/Prevention Accrual 2014 - 2017



NCORP Cancer Care Delivery Research Studies

- Cancer Care Delivery Research is a multidisciplinary science that seeks to improve clinical outcomes and patients wellbeing by intervening on patient, clinician, and organizational factors that influence care delivery
- CCDR Studies may include:
 - Patients
 - Caregivers
 - Non-patient participants (clinicians, physicians, pharmacists)
 - Practices/Organizations






NCI Tissue Procurement Studies

Patient Derived Model

100 Blood specimens Columbia NCORP Delaware/Christiana NCORP Heartland NCORP Michigan NCORP Nevada NCORP Northwest NCORP Ozark NCORP Stroger NCORP West Michigan NCORP



Blood and Tissue Pairs (1st supplement) Heartland NCORP (29)

Ozarks NCORP (28 + 8 blood only)

Early Onset Malignancy Initiative

Blood and Tissue Pairs (2nd supplement)

Ozark NCORP (36 + 3 blood only) Michigan NCORP (30) West Michigan NCORP (30) Wichita NCORP (30)


To sequence early age malignancies in 6 cancers among 4 racial/ethnic groups, M/U Sites: 82

NCORP Accrual to Precision Medicine Trials


ALCHEMIST Accruals by Organization								
Swim Lane	A15121 6	% of A151216 pts	A0 811 05	% of A081105 pts	E45 12	% of E4512 pts	EA5 142	% EA5142 pts
NCORP	1329	35.34%	75	32.33%	26	36.11%	211	40.34%

NCI Community Oncology Research Program Molecular Analysis for Therapy Choice (MATCH)

44 Percent (2788/6408) of Patients Registered for Screening in the NCI MATCH Trial are from NCORP Community and Minority Community Sites







NCORP Accrual - 2014-2017 An Academic/Community Partnership


Cancer control, prevention, screening 11,456 patients

NCTN) treatment and imaging trials 13,261 patients


Quality of Life 3,705 patients

Cancer Care Delivery Research 2838 patients and clinicians


Tissue Acquisition Studies 276 patients




NCORP Overall Minority Enrollment 2017



Minority Enrollment by Community Type





NCORP TREATMENT AND PREVENTION/CONTROL ACCRUALS ETHNICITY AND RACE


2014 - 2017

Ethnic Categories						
	Not	Hispanic or	Unknown/Not		% of All Reported	
Racial Categories	Hispanic or	Latino	Reported		Racial Categories	
	Latino		Ethnicity	TOTAL		
American Indian/Alaska	105	10			0.70/	
Native	135	18	8	161	0.7%	
Asian	681	16	13	710	3.0%	
Native Hawaiian or Other	0.0	_		102	0.417	
Pacific Islander	96	6 6	1	103	0.4%	
Black or African American	2,325	51	119	2,495	10.4%	
White	17,787	1,273	863	19,923	83.3%	
More than One Race	94	20	405	519	2.2%	
TOTAL (All Reported	21 110	440 4 204	1.407	22.014	1000/	
Racial Categories	21,118	1,384	1,407	23,911	100%	
Unknown or Not	200	371	251	822	3.4% of All Pts	
Reported	200	5/1	2.31	022	Enrolled with	
					Unknown/Not	
TOTAL	21,318	1,755	1,658	24,733	Reported Race	
4.4.77 2004.0						

11/5/2018


DCP-001: Screening Tool 10,772 Entries, 8,744 consented to DCP-001

Enrolled on a Clinical Trial: 6193/8744 (71%)




Reasons for Not Enrolling on a Clinical Trial


2,551/8744



Patient Income



Patient Education



Changes to NCORP Concept & Protocol Target Timeline Goals (Effective 8/1/2018)

Target Timeline Goals:

- **1.** Concept Receipt to Approval**120** days
- **2.** Protocol Authoring90 days
- **3. Protocol Review & Approval 175 days**
- 4. Protocol Approval to Activation 90 days
 Total Target Timeline Goal 475

NCORP Target and Absolute Goals

Concept Receipt to Protocol Activation

Target	Absolute*
475 days	525 days

Protocol Receipt to Protocol Activation (Studies without Concepts)

Target	Absolute*
265 days	315 days

*Absolute Goal = includes one additional revision cycle 50 days (Consensus Review Letter to Revision Receipt 30 days + Revision Receipt to Approval On-hold 20 days)

Trials Activated & Completed During NCORP through 7/30/2018

Protocol Number	Title	Activation date	Accrual Cut Off Date	Planned Accrual	Actual Accrual
A221301	Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Randomized, Double- Blind, Placebo-Controlled Trial	8/5/2014	4/5/2015	372	401
A221303	Randomized Study of Early Palliative Care Integrated with Standard Oncology Care Versus Standard Oncology Care Alone in Patients with Incurable Lung or Non-Colorectal Gastrointestinal Malignancies	5/15/2015	4/10/2017	400	405
A221304	A Phase III Placebo-Controlled, Randomized Three-Arm Study of Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy	11/1/2014	3/29/2017	270	275
EA1141	Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women with Dense Breasts	9/2/2016	11/7/2017	1450	1516
E4112	Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma In Situ (DCIS)	2/17/2015	4/28/2016	350	368
NRG-CC001	A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases	7/13/2015	3/12/2018	510	513
NRG-CC002	Pre-Operative Assessment and Post-Operative Outcomes of Elderly Women with Gynecologic Cancers	2/10/2015	11/2/2015	228	190
URCC-13070	Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers	10/29/2014	4/30/2017	1056	973
URCC-13091	Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue	2/26/2015	3/31/2016	75	108
URCC-14079	Effectiveness of Prophylactic Topical Agents for Radiation Dermatitis	10/13/2015	6/30/2016	180	192

Thank you!